Cabazitaxel—the taxane of choice in the new mCRPC landscape?
Crossref DOI link: https://doi.org/10.1038/nrurol.2014.144
Published Online: 2014-06-24
Published Print: 2014-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Oudard, Stéphane
Angelergues, Antoine
Text and Data Mining valid from 2014-06-24
Article History
First Online: 24 June 2014
Competing interests
: The authors declare competing interests with the following companies: Bayer, Sanofi, Astellas, Janssen, Ferring, and Ipsen.